Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smart patch help teens tame type 2 diabetes?

NCT ID NCT06089070

Knowledge-focused Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether teenagers with type 2 diabetes will wear and use a continuous glucose monitor (CGM) — a small sensor that tracks blood sugar levels. Twenty participants will use the FreeStyle Libre CGM for 6 months, while 10 others serve as a comparison group. The main goal is to see if the device is acceptable and helpful for managing their diabetes day-to-day.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FreeStyle Libre continuous glucose monitor (CGM) device
What this could lead to
If successful, this could show that CGM devices are practical and helpful for managing type 2 diabetes in teenagers.
What could go wrong
This is a small, early feasibility study with only 20 participants, so results may not apply to everyone. It focuses on whether teens will use the device, not on proving it improves health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

8 to 20 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 8- 20 years at the time of consent. 2. Clinical diagnosis of type 2 diabetes. 3. Duration of type 2 diabetes at least 4 weeks. 4. HbA1C ≥ 6.5% . 5. Stable medication regimen (No medication changes and no change in basal insulin dose by more than 20% in the 2 weeks prior to enrollment). 6. No use of CGM 90 days before screening visit. 7. English or Spanish speakers. 8. Willing to abide by recommendations and study procedures. 9. Willing and able to sign the Informed Consent Form (ICF) and/or has a parent or guardian willing and able to sign the ICF. 10. Participant and parent(s)/guardian(s) willingness to participate in all training sessions as directed by study staff. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study. Exclusion Criteria: 1. Pancreatic autoantibody positivity (GAD-65, insulin, IA-2, ICA 512, Zn-T8). 2. Plan for undergoing bariatric surgery during the study period. 3. Known history of significant mental illness or developmental delay impacting the ability to complete study activities independently. 4. Known history of adrenal insufficiency, or ongoing renal or hepatic disease. 5. Pregnancy or lactation. 6. Currently undergoing cancer treatment or systemic treatment with steroids. 7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

Contacts and locations

Locations

  • University of California San Francisco (UCSF)

    San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.